Coronary computed tomographic angiography (CCTA) employing CT scanners of 64-detector rows or greater represents a novel non-invasive method for detection of coronary artery disease (CAD), providing excellent diagnostic information when compared to invasive angiography. In addition to its high diagnostic performance, prior studies have shown that CCTA can provide important prognostic information, although these prior studies have been generally limited to small cohorts at single centers. The Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter registry, or CONFIRM, is a large, prospective, multinational, dynamic observational cohort study of patients undergoing CCTA. This registry currently represents more than 32,000 consecutive adults suspected of having CAD who underwent ≥64-detector row CCTA at 12 centers in 6 countries between 2005 and 2009. Based on its large sample size and adequate statistical power, the data derived from CONFIRM registry have and will continue to provide key answers to many important topics regarding CCTA. Based on its multisite international national design, the results derived from CONFIRM should be considered as more generalizable than prior smaller single-center studies. This article summarizes the current status of several studies from CONFIRM registry.
Bibliographical noteFunding Information:
Dr Min received modest speakers’ bureau and medical advisory board compensation and significant research support from GE Healthcare. Dr Achenbach received grant support from Siemens and Bayer Schering Pharma and has served as a consultant for Servier. Dr Al-Mallah received support from the American Heart Association, BCBS Foundation of Michigan, and Astellas. Dr Cademartiri received grant support from GE Healthcare and has served on the Speakers’ Bureau of Bracco and as a consultant for Servier. Dr Maffei received grant support from GE Healthcare. Dr Chinnaiyan received grant support from Bayer Pharma and Blue Cross Blue Shield Blue Care MI. Dr Chow received research and fellowship support from GE Healthcare, research support from Pfizer and AstraZeneca, and educational support from TeraRecon. Dr Hausleiter received a research grant from Siemens Medical Systems. Dr Kaufmann received institutional research support from GE Healthcare and grant support from Swiss National Science Foundation. Dr Maffei received grant support from GE Healthcare. Dr Raff received grant support from Siemens, Blue Cross Blue Shield Blue Care MI, and Bayer Pharma. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
All Science Journal Classification (ASJC) codes
- Radiology Nuclear Medicine and imaging
- Cardiology and Cardiovascular Medicine